IMMP
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Friday, June 2, 2023 BiopharmaWatch Research 1 min read Key Takeaway: Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer
Price reaction · baseline $2.01 (2023-05-30 close) · hit after-hours · 4 other IMMP headline(s) in the window, move may be shared
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Full Press Release Details
Immutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offer.